BioSpace News Archive

RepliCel Life Sciences Inc. is pleased to announce the filing of a new patent application covering novel aspects of the DermaPrecise™ product portfolio as well as the granting and/or allowance of three patent applications in key markets.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present at 2:15 p.m. ET at the 40th Annual JP Morgan Healthcare Conference.

Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that Co-Diagnostics will be featured at the H.C. Wainwright & Co. 2022 BioConnect Conference, being held virtually on January 10-13.

BIOLASE, Inc., the global leader in dental lasers, announced preliminary 2021 fourth quarter revenue results that are significantly above fourth quarter revenue for both 2020 and pre-COVID 2019.

HotSpot Therapeutics, Inc. and Caris Life Sciences® announced a strategic partnership to advance precision medicine approaches for HotSpot’s emerging product portfolio.

NovaBay® Pharmaceuticals, Inc. announces the expansion of its Avenova brand with the launch of its Lubricant Eye Drops.

Treace Medical Concepts, Inc., a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus, announced preliminary unaudited results for fourth quarter and full year 2021.

Foghorn® Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced Steven Bellon, Ph.D., currently Senior Vice President of Drug Discovery, is promoted to Chief Scientific Officer, effective, January 10, 2022.

C4 Therapeutics, Inc. announced strategic priorities and 2022 milestones to advance its targeted protein degradation portfolio.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2021.